Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
ALLK - Allakos Inc
$128.51
-0.04(-0.03%)9:00:01 PM 1/15/2021
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.
Stock Chart

Summary:

  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    01/14/2021ALLK
    Here's Why We're Not At All Concerned With Allakos' (NASDAQ:ALLK) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

    01/6/2021ALLK
    Are Options Traders Betting on a Big Move in Allakos (ALLK) Stock?

    Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

    12/22/2020ALLK
    Allakos Appoints Natalie Holles to its Board of Directors

    REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors. “Natalie’s extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide val...

    12/21/2020ALLK
    Benzinga's Top Upgrades, Downgrades For December 21, 2020

    Upgrades * According to Truist Securities, the prior rating for Fox Factory Holding Corp (NASDAQ:FOXF) was changed from Hold to Buy. In the third quarter, Fox Factory Hldg showed an EPS of $1.07, compared to $0.83 from the year-ago quarter. The current stock performance of Fox Factory Hldg shows a 52-week-high of $113.41 and a 52-week-low of $34.58. Moreover, at the end of the last trading period, the closing price was at $102.14. * Northcoast Research upgraded the previous rating for Manpowe...

    12/11/2020ALLK
    Is ALLK A Good Stock To Buy Now?

    Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the third quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]

    11/9/2020ALLK
    Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update

    REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update of its ongoing development activities. Business Updates * Announced positive results from our prospective prevalence study showing that 45% (181/405) of symptomatic patients ...

    11/2/2020ALLK
    Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

    REDWOOD CITY, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020 Virtual Annual Scientific Meeting. The presentation details were as follows:   Title:High Discovery Rate of Previously Undiagnosed Patients with Eosinophilic Gastritis and Duodenitis Using a Systematic E...

    10/29/2020ALLK
    Allakos Announces Pricing of Public Offering of Common Stock

    REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced the pricing of its previously announced underwritten public offering. The size of the offering is $250 million of shares of its common stock. The Company is offering 3,048,781 shares at a public offering price of $82.00 per share. The offering is expected to close on November 2...

    10/28/2020ALLK
    The Daily Biotech Pulse: Sanofi-GlaxoSmithKline To Supply 200M Doses To COVID-19 Vaccine Alliance, Gilead Earnings, Biodesix Debuts

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 27) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) * Ascendis Pharma A/S (NASDAQ: ASND) * BioLife Solutions Inc (NASDAQ: BLFS) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * Denali Therapeutics Inc (NASDAQ: DNLI) * EXACT Sciences Corporation (NASDAQ: EXAS) ( announced two acquisitions and also reported bette...